Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when OTLK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOutlook Therapeutics raises $5M at $0.31/share, reprices old warrants 86% lower to $0.31
Filed April 23, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Sold 16.1M shares at $0.31 with matching warrants, raising ~$5M gross; warrants exercisable only after shareholder approval of share issuance and authorized share increase (meeting within 90 days).
Item 8.01 verify on EDGAR → -
high
Repriced 2.1M existing warrants from $2.26 to $0.31 (86% reduction) for a participating investor, making previously out-of-the-money warrants immediately in-the-money at the offering price.
Item 8.01 verify on EDGAR → -
high
Full warrant exercise would add 16.1M shares (roughly doubling dilution from this round); warrants expire five years after effectiveness and shareholder approval.
Item 8.01 verify on EDGAR → -
medium
Placement agent H.C. Wainwright received 8% cash fees plus warrants for 1.1M shares at $0.3875 (7% of shares sold), with additional fees on future warrant exercises.
Item 8.01 verify on EDGAR → -
medium
Net proceeds of ~$4.5M (after fees) allocated to working capital and general corporate purposes; no specific runway or program funding disclosed.
Item 8.01 verify on EDGAR →
Summary
Outlook Therapeutics raised approximately $5 million by selling 16.1 million shares at $0.31 each, with each share accompanied by a warrant to purchase one additional share at the same $0.31 price. The warrants cannot be exercised until shareholders approve both the share issuance and an increase in authorized shares, with a meeting required within 90 days of the April 23 closing.
If fully exercised, the warrants would add another 16.1 million shares, roughly doubling the dilution from this financing round. The low price point and substantial share count signal meaningful dilution for existing holders. The company also repriced 2.1 million existing warrants from a $2.26 exercise price down to $0.31—an 86% reduction—for an investor participating in the new offering.
This amendment converts previously out-of-the-money warrants into in-the-money instruments at the current offering price, benefiting the holder at the expense of other shareholders and indicating the stock has declined substantially since the warrants were issued in January 2025. After placement agent fees of 8% and expenses, net proceeds are likely around $4.5 million, earmarked for working capital and general corporate purposes with no specific program funding or runway extension disclosed.
Section-by-Section Diff
Event · Item 3.02 — Unregistered Sales of Equity Securities
Unregistered equity securities sale disclosed; details cross-referenced to Item 1.01.
Added in current filing · verify on EDGAR →
Reference is made to the disclosure under
The 8-K discloses an unregistered sale of equity securities under Item 3.02, with details cross-referenced to Item 1.01. The filing text is truncated and does not provide the complete disclosure, including the nature of the securities, the purchasers, the consideration received, or the exemption relied upon. Without the full text, the materiality and investor impact cannot be assessed.
Event · Item 8.01 — Other Events
OTLK raised ~$5M via registered direct offering of 16.1M shares at $0.31 plus warrants; amended prior warrants to lower exercise price from $2.26 to $0.31.
Added in current filing · verify on EDGAR →
Pursuant to the Engagement Letter, the Company agreed to pay to the Placement Agent (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds received in the Offering and (iii) to reimburse the Placement Agent for certain expenses incurred by the Placement Agent in connection with the Offering. In addition, under the Engagement Letter, the Company agreed to issue to the Placement Agent (or its designees) warrants (the “Placement Agent Warrants”) to purchase 1,129,032 shares of Common Stock (equal to 7.0% of the aggregate number of shares of Common Stock sold in the Offering). The Placement Agent Warrants have an exercise price of $0.3875 per share (which is 125% of the offering price per share of Common Stock and accompanying Common Warrant in the Offering) and will be exercisable on the Initial Exercise Date.
H.C. Wainwright received 8% cash fees ($400,000 on $5M gross proceeds) plus warrants to purchase 1,129,032 shares at $0.3875, representing 7% of the shares sold. Additionally, the placement agent receives 8% fees and 7% warrant coverage on any future cash exercises of the investor warrants, creating ongoing dilution tied to warrant exercises.
Added in current filing · verify on EDGAR →
The Company currently plans to use the net proceeds from the Offering primarily for working capital and general corporate purposes. The gross proceeds from the Offering were approximately $5.0 million, prior to deducting the Placement Agent’s fees and other offering expenses payable by the Company.
The company raised approximately $5.0 million gross, with net proceeds after 8% placement fees and expenses likely around $4.5 million or less, to be used for working capital and general corporate purposes. No specific allocation or runway extension was disclosed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify